The Zhitong Finance App learned that Conoa-B (02162) once fell by more than 16%. As of press release, it fell 13.77% to HK$69.85, with a turnover of HK$548 million.

According to the news, CLDN18.2 ADC Sone-VE announced Clarity Level 01 at Chairman's Forum II is the world's first stage III to prove significant OS benefits in second-line and post-stage CLDN 18.2 positive advanced gastric cancer: OS 10.0 months versus 5.0 months (HR 0.47) for third-tier and later-line people, and OS 10.6 months versus 6.4 months (HR 0.58) for second-line and backline people. However, the PFS in the two main endpoints was only 4.2 months versus 3.8 months, and the difference was not statistically significant.

According to reports, Sone-VE, formerly known as CMG901, is a Claudin18.2 ADC developed by KYM (both parties hold 70% and 30% shares, respectively), a joint venture between Conoah and Lepu Biotech. According to Dingxiangyuan, Professor Luo Suxia said that in advanced gastrointestinal cancer clinical trials, it is not uncommon for PFS and OS results to not be completely synchronized, and the clinical value of a drug cannot be judged based on just one of the indicators.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.